Amphastar Pharmaceuticals
AMPH
211 hedge funds and large institutions have $572M invested in Amphastar Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 63 increasing their positions, 76 reducing their positions, and 33 closing their positions.
167% more call options, than puts
Call options by funds: $561K | Put options by funds: $210K
3% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 33
2% less funds holding
Funds holding: 215 → 211 (-4)
7.07% less ownership
Funds ownership: 71.3% → 64.22% (-7.1%)
10% less capital invested
Capital invested by funds: $634M → $572M (-$62M)
17% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 76
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$6.68M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.59M |
| 3 |
D.E. Shaw & Co
New York
|
+$4.47M |
| 4 |
Goldman Sachs
New York
|
+$3.55M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$3.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$30.2M |
| 2 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
-$18.5M |
| 3 |
EIP
Epoch Investment Partners
New York
|
-$17.6M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$9.01M |
| 5 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$8.99M |
AMPH Hedge Fund Activity: Q2 2026 in Review
211 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q2 2026, worth a combined $572M — down 9.8% from $634M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of AMPH and 32 opened new positions — a net loss of 1 holder — while 76 trimmed existing stakes and 63 added.
The largest buyer was HRT Financial, adding an estimated $6.68M. The largest seller was TD Asset Management, exiting entirely with an estimated $30.2M sold.
- 211 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q2 2026, down from 215 in Q1 2026.
- Funds reported $572M of Amphastar Pharmaceuticals stock for Q2 2026, down 9.8% quarter-over-quarter.
- 32 funds opened new Amphastar Pharmaceuticals positions in Q2 2026 and 33 closed out, a net change of -1 holder.
- The largest Amphastar Pharmaceuticals buyer in Q2 2026 was HRT Financial, an estimated $6.68M added.
- The largest Amphastar Pharmaceuticals seller in Q2 2026 was TD Asset Management, an estimated $30.2M sold.
Based on aggregated 13F filings for Q2 2026.